Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE